On Wednesday, the U.S. House Judiciary Committee voted to approve three bills to restrain practices drugmakers use to raise prices and fend off competition, including a bill to ban the tactic of paying generic companies to delay bringing cheaper versions of their medicines to market.

Committee Chairman Jerrold Nadler said that the Congressional Budget Office had estimated that banning so-called pay-for-delay patent deals used to stall generic competition – the subject of one of the bills – would save Americans more than half a billion dollars over 10 years.

The measures were introduced in a rare hearing that mixed members of the House and Senate, during which lawmakers from both parties and from both chambers stated that they had introduced the bills with the aim to lower the cost of prescription medicines for Americans. Four identical bills were introduced in the House and Senate.

The House Judiciary Committee voted on Wednesday to enable the Federal Trade Commission to ban sham citizen petitions, in which drug companies petition the U.S. Food and Drug Administration about a generic company seeking approval for a rival drug with the goal of delaying its market entry.

Brand name drugs can fairly quickly lose more than 80% of their sales revenue once multiple generic versions reach the market.

Also they have approved a measure to stop product-hopping that the practice of making a minor tweak to the formula of a medication to win a new patent and therefore a longer period of exclusivity, and would also stop pay-for-delay patent deals.

The Senate Judiciary Committee approved the measures in July, all on a voice vote.

The House Judiciary committee is set to vote on Thursday on the last measure, which would make it easier to bring to market biosimilars, cheaper versions of expensive biotech drugs that cannot be exactly duplicated, unlike pills.

The measures must next be taken up by the full House and Senate.